By Jayne Lawrence, Head of Division of Pharmacy and Optometry, University of Manchester.
The Commissioning Framework for Biological Medicines announced recently by NHS England will both help guide improvements to developing better medicines for patients and provide a guide to ensuring the NHS gets best value for money from these innovative, exciting medicines.
What is a biologic?
Biological medicines have made many new, groundbreaking treatments possible, significantly im-proving the lives of many patients with long term conditions such as diabetes, arthritis, anaemia associated with chronic kidney failure, and types of cancer.
They are extremely expensive, in part due to the complexity of their production. For example, a course of a new immunotherapy drug typically costs more than £100,000 per patient per year. Furthermore, as biologicals currently comprise approximately 50% of all new drug approvals, it is likely that the high cost of new medicines is with us for the foreseeable future. Consequently, any way of reducing the cost of these important medicines is vital. Read more Biologics and biosimilars – what are they?